Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Average Recommendation of “Hold” from Analysts

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have received a consensus rating of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $12.75.

A number of research firms have recently commented on MRNS. StockNews.com raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Marinus Pharmaceuticals in a research report on Wednesday. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday. Finally, Truist Financial reiterated a “buy” rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th.

Marinus Pharmaceuticals Trading Up 10.9 %

NASDAQ:MRNS opened at $1.22 on Friday. The firm’s fifty day moving average is $1.33 and its 200-day moving average is $4.40. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.93 and a current ratio of 3.07. Marinus Pharmaceuticals has a 52 week low of $1.05 and a 52 week high of $11.26. The firm has a market cap of $67.02 million, a P/E ratio of -0.46 and a beta of 1.13.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of MRNS. Vanguard Group Inc. raised its holdings in Marinus Pharmaceuticals by 1.2% during the third quarter. Vanguard Group Inc. now owns 2,577,475 shares of the biopharmaceutical company’s stock worth $20,749,000 after buying an additional 31,233 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at about $134,000. abrdn plc purchased a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at about $6,006,000. Trexquant Investment LP purchased a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at about $553,000. Finally, Franklin Resources Inc. raised its holdings in shares of Marinus Pharmaceuticals by 1.3% in the fourth quarter. Franklin Resources Inc. now owns 3,833,955 shares of the biopharmaceutical company’s stock valued at $41,675,000 after purchasing an additional 49,589 shares during the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.